Stocks Health care ATTO
NASDAQ · Health careAttovia Therapeutics, Inc. (ATTO)
At September 30, 2026 it held $115.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Attovia Therapeutics, Inc.
- Net worth
- Attovia Therapeutics, Inc. has a market value (market cap) of $738.4M at the latest share price, and shareholders' equity of $397.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
What Attovia Therapeutics, Inc. does
Attovia Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ATTO.
Earnings: every quarter and the next report date
Latest SEC filings
What Attovia Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- September 2, 2026
- September 2, 2026
- August 12, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026Activist stake (5% or more) SCHEDULE 13D
- August 6, 2026
- August 6, 2026
- August 4, 2026
- July 29, 2026
Insider trades
What the people running Attovia Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 6, 2026 | Goldman Sachs Group IncFormer 10% Owner | Exercised optionsindirect | 1,957,134 | - |
| August 6, 2026 | Goldman Sachs Group IncFormer 10% Owner | Exercised optionsindirect | 478,498 | - |
| August 6, 2026 | Goldman Sachs Group IncFormer 10% Owner | Boughtindirect | 500,000 | $8.5M |
| August 6, 2026 | Walsh ColinDirector | Exercised optionsindirect | 1,957,134 | - |
| August 6, 2026 | Walsh ColinDirector | Exercised optionsindirect | 478,498 | - |
| August 6, 2026 | Walsh ColinDirector | Boughtindirect | 500,000 | $8.5M |
| August 6, 2026 | venBio Global Strategic Fund IV, L.P.10% owner | Exercised options | 2,311,870 | - |
| August 6, 2026 | venBio Global Strategic Fund IV, L.P.10% owner | Exercised options | 821,998 | - |
Who owns ATTO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Frazier Life Sciences XI, L.P.13D, may seek influence with 8 related filers | 13.5% | August 11, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 7.45% | August 12, 2026 |
Largest institutional holders
Insiders
7 insiders reported holding 21,582,545 shares in total, about $349.6M at the last price.
| Holder | Shares |
|---|---|
| Frazier Life Sciences XI, L.P.10% owner | 6,154,213 |
| venBio Global Strategic Fund IV, L.P.10% owner | 4,181,367 |
| Goldman Sachs Group IncFormer 10% Owner | 3,020,6323,020,632 held indirectly |
| Walsh ColinDirector | 3,020,6323,020,632 held indirectly |
| Redmile Group, LLC10% owner | 2,165,7081,182,854 held indirectly |
| Deep Track Biotechnology Master Fund, Ltd.10% owner | 1,957,138 |
| Sanofi10% owner | 1,082,8551,082,855 held indirectly |
Questions about ATTO
What does Attovia Therapeutics, Inc. do?
Attovia Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ATTO. Its shares trade on NASDAQ under the ticker ATTO.
What is Attovia Therapeutics, Inc.'s net worth?
Attovia Therapeutics, Inc. has a market value (market cap) of $738.4M at the latest share price, and shareholders' equity of $397.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
When did Attovia Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
Similar companies
Compare ATTO with
Follow ATTO
Get an email when Attovia Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Attovia Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.